Patents Assigned to Synthetic Biologics, Inc.
  • Publication number: 20200390742
    Abstract: The present invention relates to, in part, methods and compositions for the treatment of methanogen-associated disorders such as, for example, Irritable Bowel Syndrome (IBS). Particularly, modified-release formulations comprising at least one antimethanogenic statin are provided which release the antimethanogenic statin in the intestines.
    Type: Application
    Filed: June 21, 2017
    Publication date: December 17, 2020
    Applicants: Cedars-Sinai Medical Center, Synthetic Biologics, Inc.
    Inventors: Vincent John Wacher, Mark Pimentel
  • Patent number: 10828260
    Abstract: The present invention provides, in part, formulations comprising a beta-lactamase. Particularly, modified-release formulations comprising a beta-lactamase are provided which release a substantial amount of the beta-lactamase in the intestines. Therapeutic uses of the beta-lactamase formulations are also provided.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: November 10, 2020
    Assignee: Synthetic Biologics, Inc.
    Inventors: Andrew Bristol, Michael Kaleko, Sheila Connelly
  • Publication number: 20200323781
    Abstract: The present invention relates to, in part, methods and compositions for the treatment of methanogen-associated disorders such as, for example, Irritable Bowel Syndrome (IBS). Particularly, modified-release formulations comprising at least one antimethanogenic statin are provided which release the antimethanogenic statin in the intestines.
    Type: Application
    Filed: April 27, 2020
    Publication date: October 15, 2020
    Applicants: Cedars-Sinai Medical Center, Synthetic Biologics, Inc.
    Inventors: Mark Pimentel, Ruchi Mathur, Steve Kanzer, Vince Wacher
  • Patent number: 10792346
    Abstract: This invention provides, in part, various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption.
    Type: Grant
    Filed: July 10, 2018
    Date of Patent: October 6, 2020
    Assignee: Synthetic Biologics, Inc.
    Inventors: Michael Kaleko, Sheila Connelly, Vincent John Wacher
  • Patent number: 10767171
    Abstract: This invention relates to, in part, compositions of beta-lactamases and methods of using these enzymes in, for example, gastrointestinal tract (GI tract) disorders such as C. difficile infection (CDI).
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: September 8, 2020
    Assignee: Synthetic Biologics, Inc.
    Inventors: Michael Kaleko, Sheila Connelly
  • Patent number: 10736871
    Abstract: The present invention relates to, in part, methods for the treatment of methanogen-associated disorders such as, for example, Irritable Bowel Syndrome (IBS) using at least one anti-methanogenic lovastatin analog or derivative. In addition, modified-release formulations comprising at least one anti-methanogenic lovastatin analog or derivative are provided which release the anti-methanogenic lovastatin analog or derivative in the gastrointestinal tract.
    Type: Grant
    Filed: March 31, 2016
    Date of Patent: August 11, 2020
    Assignees: Cedars-Sinai Medical Center, Synthetic Biologics, Inc.
    Inventors: Mark Pimentel, Vince Wacher
  • Patent number: 10709773
    Abstract: The present invention relates to, inter alia, safe and effective doses of a beta-lactamase for, e.g. microbiome protection.
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: July 14, 2020
    Assignee: Synthetic Biologics, Inc.
    Inventor: Joseph Sliman
  • Patent number: 10584326
    Abstract: This invention relates to, in part, compositions of beta-lactamases and methods of using these enzymes in, for example, gastrointestinal tract (GI tract) disorders such as C. difficile infection (CDI).
    Type: Grant
    Filed: May 16, 2019
    Date of Patent: March 10, 2020
    Assignee: Synthetic Biologics, Inc.
    Inventors: Michael Kaleko, Sheila Connelly
  • Patent number: 10548955
    Abstract: This invention relates, in part, to various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: February 4, 2020
    Assignee: Synthetic Biologics, Inc.
    Inventors: Michael Kaleko, Sheila Connelly
  • Patent number: 10526400
    Abstract: The present invention relates to humanized antibodies which bind the pertussis toxin protein and their use as therapeutic agents. In particular, the present invention is directed to improved humanized 1B7 and 11E6 antibodies which bind the pertussis toxin protein.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: January 7, 2020
    Assignees: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, SYNTHETIC BIOLOGICS, INC.
    Inventors: Jennifer Maynard, Annalee Nguyen, Eduardo Padlan, Ellen Wagner
  • Publication number: 20190328885
    Abstract: The present invention relates to, in part, methods and compositions for the treatment of methanogen-associated disorders such as, for example, Irritable Bowel Syndrome (IBS). Particularly, modified-release formulations comprising at least one antimethanogenic statin are provided which release the antimethanogenic statin in the intestines.
    Type: Application
    Filed: May 7, 2019
    Publication date: October 31, 2019
    Applicants: Cedars-Sinai Medical Center, Synthetic Biologics, Inc.
    Inventors: Mark Pimentel, Ruchi Mathur, Steve Kanzer, Vince Wacher
  • Patent number: 10336995
    Abstract: This invention relates to, in part, compositions of beta-lactamases and methods of using these enzymes in, for example, gastrointestinal tract (GI tract) disorders such as C. difficile infection (CDI).
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: July 2, 2019
    Assignee: SYNTHETIC BIOLOGICS, INC.
    Inventors: Michael Kaleko, Sheila Connelly
  • Patent number: 10253306
    Abstract: The present invention relates to pharmaceuticals and modified beta-lactamases. Specifically, the invention relates to novel recombinant beta-lactamases and pharmaceutical compositions comprising the beta-lactamases. Also, the present invention relates to methods for modifying a beta-lactamase, producing the beta-lactamase and treating or preventing beta-lactam antibiotic induced adverse effects. Furthermore, the present invention relates to the beta-lactamase for use as a medicament and to the use of the beta-lactamase in the manufacture of a medicament for treating or preventing beta-lactam antibiotics induced adverse effects. Still further, the invention relates to a polynucleotide and a host cell comprising the polynucleotide.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: April 9, 2019
    Assignee: SYNTHETIC BIOLOGICS, INC.
    Inventors: Pertti Koski, Ulla Airaksinen, Katja Valimaki
  • Patent number: 10105322
    Abstract: The present invention provides, in part, formulations comprising a beta-lactamase. Particularly, modified-release formulations comprising a beta-lactamase are provided which release a substantial amount of the beta-lactamase in the intestines. Therapeutic uses of the beta-lactamase formulations are also provided.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: October 23, 2018
    Assignee: SYNTHETIC BIOLOGICS, INC.
    Inventors: Andrew Bristol, Michael Kaleko, Sheila Connelly
  • Publication number: 20180289667
    Abstract: The present invention relates to, in part, methods for the treatment of methanogen-associated disorders such as, for example, Irritable Bowel Syndrome (IBS) using at least one anti-methanogenic lovastatin analog or derivative. In addition, modified-release formulations comprising at least one anti-methanogenic lovastatin analog or derivative are provided which release the anti-methanogenic lovastatin analog or derivative in the gastrointestinal tract.
    Type: Application
    Filed: March 31, 2016
    Publication date: October 11, 2018
    Applicants: Cedars-Sinai Medical Center, Synthetic Biologics, Inc.
    Inventors: Mark PIMENTEL, Vince WACHER
  • Publication number: 20180289816
    Abstract: The present invention relates to, in part, methods and compositions for the treatment of methanogen-associated disorders such as, for example, Irritable Bowel Syndrome (IBS). Particularly, modified-release formulations comprising at least one antimethanogenic statin are provided which release the antimethanogenic statin in the intestines.
    Type: Application
    Filed: March 29, 2018
    Publication date: October 11, 2018
    Applicants: Cedars-Sinai Medical Center, Synthetic Biologics, Inc.
    Inventors: Mark Pimentel, Ruchi Mathur, Steve Kanzer, Vince Wacher
  • Patent number: 10087433
    Abstract: This invention relates to, in part, compositions of beta-lactamases and methods of using these enzymes in, for example, gastrointestinal tract (GI tract) disorders such as C. difficile infection (CDI).
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: October 2, 2018
    Assignee: SYNTHETIC BIOLOGICS, INC.
    Inventors: Michael Kaleko, Sheila Connelly
  • Patent number: 10046035
    Abstract: This invention provides, in part, various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption.
    Type: Grant
    Filed: July 5, 2017
    Date of Patent: August 14, 2018
    Assignee: SYNTHETIC BIOLOGICS, INC.
    Inventors: Michael Kaleko, Sheila Connelly, Vincent John Wacher
  • Patent number: 10041056
    Abstract: The present invention relates to pharmaceuticals and modified beta-lactamases. Specifically, the invention relates to novel recombinant beta-lactamases and pharmaceutical compositions comprising the beta-lactamases. Also, the present invention relates to methods for modifying a beta-lactamase, producing the beta-lactamase and treating or preventing beta-lactam antibiotic induced adverse effects. Furthermore, the present invention relates to the beta-lactamase for use as a medicament and to the use of the beta-lactamase in the manufacture of a medicament for treating or preventing beta-lactam antibiotics induced adverse effects. Still further, the invention relates to a polynucleotide and a host cell comprising the polynucleotide.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: August 7, 2018
    Assignee: Synthetic Biologics, Inc.
    Inventors: Pertti Koski, Ulla Airaksinen, Katja Valimaki
  • Patent number: 10035846
    Abstract: The present invention relates to humanized antibodies which bind the pertussis toxin protein and their use as therapeutic agents. In particular, the present invention is directed to improved humanized 1B7 and 11E6 antibodies which bind the pertussis toxin protein.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: July 31, 2018
    Assignees: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, SYNTHETIC BIOLOGICS, INC.
    Inventors: Jennifer Maynard, Annalee Nguyen, Eduardo Padlan, Ellen Wagner